New Drug Dapoxetine Helps Counter Premature Ejaculation
Two major clinical trial results suggest that the anti-depressant drug Dapoxetine is effective for the treatment of premature ejaculation. The trials examined the effects of the drug on 2,614 men, and found that it increased ejaculation time 300%, from 1 to 3 minutes in the subjects in the trial.
According to the study, published in The Lancet, "common adverse events (30 mg and 60 mg dapoxetine, respectively) were nausea (8.7%, 20.1%), diarrhoea (3.9%, 6.8%), headache (5.9%, 6.8%), and dizziness (3.0%, 6.2%)."
Dapoxetine is in a class of drugs called selective serotonin reuptake inhibitor (SSRI). In October, 2005 the FDA declined to approve the drug. Although they are not indicated for the treatment of PE, conventional selective serotonin reuptake inhibitor (SSRI) antidepressants are commonly used to treat the condition.
In December, 2000 ALZA exclusively licensed PPD GenuPro's compound, dapoxetine, for genitourinary therapies, including premature ejaculation.
Alza Corporation, the drug's manufacturer, continues to work toward addressing the FDA's concerns.
If approved by the FDA, dapoxetine hydrochloride would be the first prescription treatment designed specifically to treat Premature Ejaculation and will be marketed in the U.S. by Ortho-McNeil Pharmaceutical, Inc.
More Info:
- The Lancet: Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials (Abstract) (Free subscription required)
- Medical News Today: Dapoxetine Safe And Effective In Treating Premature Ejaculation
